These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 16945014)

  • 1. Enzyme fragment complementation binding assay for p38alpha mitogen-activated protein kinase to study the binding kinetics of enzyme inhibitors.
    Zaman GJ; van der Lee MM; Kok JJ; Nelissen RL; Loomans EE
    Assay Drug Dev Technol; 2006 Aug; 4(4):411-20. PubMed ID: 16945014
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The design, synthesis, and evaluation of 8 hybrid DFG-out allosteric kinase inhibitors: a structural analysis of the binding interactions of Gleevec, Nexavar, and BIRB-796.
    Dietrich J; Hulme C; Hurley LH
    Bioorg Med Chem; 2010 Aug; 18(15):5738-48. PubMed ID: 20621496
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of imatinib and sorafenib binding to p38alpha compared with c-Abl and b-Raf provides structural insights for understanding the selectivity of inhibitors targeting the DFG-out form of protein kinases.
    Namboodiri HV; Bukhtiyarova M; Ramcharan J; Karpusas M; Lee Y; Springman EB
    Biochemistry; 2010 May; 49(17):3611-8. PubMed ID: 20337484
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fluorescence polarization binding assay to develop inhibitors of inactive p38alpha mitogen-activated protein kinase.
    Munoz L; Selig R; Yeung YT; Peifer C; Hauser D; Laufer S
    Anal Biochem; 2010 Jun; 401(1):125-33. PubMed ID: 20175985
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tetra-substituted pyridinylimidazoles as dual inhibitors of p38α mitogen-activated protein kinase and c-Jun N-terminal kinase 3 for potential treatment of neurodegenerative diseases.
    Muth F; Günther M; Bauer SM; Döring E; Fischer S; Maier J; Drückes P; Köppler J; Trappe J; Rothbauer U; Koch P; Laufer SA
    J Med Chem; 2015 Jan; 58(1):443-56. PubMed ID: 25475894
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design and synthesis of novel p38α MAP kinase inhibitors: discovery of pyrazole-benzyl ureas bearing 2-molpholinopyrimidine moiety.
    Arai T; Ohno M; Inoue H; Hayashi S; Aoki T; Hirokawa H; Meguro H; Koga Y; Oshida K; Kainoh M; Suyama K; Kawai H
    Bioorg Med Chem Lett; 2012 Aug; 22(15):5118-22. PubMed ID: 22749282
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular dynamics simulation and free energy calculation studies of the binding mechanism of allosteric inhibitors with p38α MAP kinase.
    Yang Y; Shen Y; Liu H; Yao X
    J Chem Inf Model; 2011 Dec; 51(12):3235-46. PubMed ID: 22097958
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pyridinyl imidazole inhibitors of p38 mitogen-activated protein kinase bind in the ATP site.
    Young PR; McLaughlin MM; Kumar S; Kassis S; Doyle ML; McNulty D; Gallagher TF; Fisher S; McDonnell PC; Carr SA; Huddleston MJ; Seibel G; Porter TG; Livi GP; Adams JL; Lee JC
    J Biol Chem; 1997 May; 272(18):12116-21. PubMed ID: 9115281
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-content screening analysis of the p38 pathway: profiling of structurally related p38alpha kinase inhibitors using cell-based assays.
    Ross S; Chen T; Yu V; Tudor Y; Zhang D; Liu L; Tamayo N; Dominguez C; Powers D
    Assay Drug Dev Technol; 2006 Aug; 4(4):397-409. PubMed ID: 16945013
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The design, synthesis and potential utility of fluorescence probes that target DFG-out conformation of p38alpha for high throughput screening binding assay.
    Tecle H; Feru F; Liu H; Kuhn C; Rennie G; Morris M; Shao J; Cheng AC; Gikunju D; Miret J; Coli R; Xi SH; Clugston SL; Low S; Kazmirski S; Ding YH; Cao Q; Johnson TL; Deshmukh GD; DiNitto JP; Wu JC; English JM
    Chem Biol Drug Des; 2009 Dec; 74(6):547-59. PubMed ID: 19843080
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery and characterization of MAPK-activated protein kinase-2 prevention of activation inhibitors.
    Cumming JG; Debreczeni JÉ; Edfeldt F; Evertsson E; Harrison M; Holdgate GA; James MJ; Lamont SG; Oldham K; Sullivan JE; Wells SL
    J Med Chem; 2015 Jan; 58(1):278-93. PubMed ID: 25255283
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fluorescence polarization-based assays for detecting compounds binding to inactive c-Jun N-terminal kinase 3 and p38α mitogen-activated protein kinase.
    Ansideri F; Lange A; El-Gokha A; Boeckler FM; Koch P
    Anal Biochem; 2016 Jun; 503():28-40. PubMed ID: 26954235
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, synthesis and anti-inflammatory activity of imidazol-5-yl pyridine derivatives as p38α/MAPK14 inhibitor.
    Ali EMH; Abdel-Maksoud MS; Hassan RM; Mersal KI; Ammar UM; Se-In C; He-Soo H; Kim HK; Lee A; Lee KT; Oh CH
    Bioorg Med Chem; 2021 Feb; 31():115969. PubMed ID: 33422910
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human p38α mitogen-activated protein kinase in the Asp168-Phe169-Gly170-in (DFG-in) state can bind allosteric inhibitor Doramapimod.
    Suplatov D; Kopylov K; Sharapova Y; Švedas V
    J Biomol Struct Dyn; 2019 May; 37(8):2049-2060. PubMed ID: 29749295
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of a fluorescent-tagged kinase assay system for the detection and characterization of allosteric kinase inhibitors.
    Simard JR; Getlik M; Grütter C; Pawar V; Wulfert S; Rabiller M; Rauh D
    J Am Chem Soc; 2009 Sep; 131(37):13286-96. PubMed ID: 19572644
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The activation state of p38 mitogen-activated protein kinase determines the efficiency of ATP competition for pyridinylimidazole inhibitor binding.
    Frantz B; Klatt T; Pang M; Parsons J; Rolando A; Williams H; Tocci MJ; O'Keefe SJ; O'Neill EA
    Biochemistry; 1998 Sep; 37(39):13846-53. PubMed ID: 9753474
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, synthesis, biological evaluation, and docking studies of novel (imidazol-5-yl)pyrimidine-based derivatives as dual BRAF
    Ali EMH; El-Telbany RFA; Abdel-Maksoud MS; Ammar UM; Mersal KI; Zaraei SO; El-Gamal MI; Choi SI; Lee KT; Kim HK; Lee KH; Oh CH
    Eur J Med Chem; 2021 Apr; 215():113277. PubMed ID: 33601311
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and evaluation of the epithelial-to- mesenchymal inhibitory activity of indazole-derived imidazoles as dual ALK5/p38α MAP inhibitors.
    Liu YY; Guo Z; Wang JY; Wang HM; Da Qi J; Ma J; Piao HR; Jin CH; Jin X
    Eur J Med Chem; 2021 Apr; 216():113311. PubMed ID: 33677350
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site.
    Pargellis C; Tong L; Churchill L; Cirillo PF; Gilmore T; Graham AG; Grob PM; Hickey ER; Moss N; Pav S; Regan J
    Nat Struct Biol; 2002 Apr; 9(4):268-72. PubMed ID: 11896401
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Switch control pocket inhibitors of p38-MAP kinase. Durable type II inhibitors that do not require binding into the canonical ATP hinge region.
    Ahn YM; Clare M; Ensinger CL; Hood MM; Lord JW; Lu WP; Miller DF; Patt WC; Smith BD; Vogeti L; Kaufman MD; Petillo PA; Wise SC; Abendroth J; Chun L; Clark R; Feese M; Kim H; Stewart L; Flynn DL
    Bioorg Med Chem Lett; 2010 Oct; 20(19):5793-8. PubMed ID: 20800479
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.